期刊文献+

促进环孢素A大鼠肠道吸收的机制与剂型因素研究 被引量:1

Studies on Mechanism to Promote Intestinal Absorption of Cyclosporine A & Formulation Factors
原文传递
导出
摘要 目的:考察促进环孢素A(cyclosporine A,CsA)肠道吸收的机制及其剂型因素。方法:与CsA胶囊(商品名:新山地明,Neoral)为对照,比较CsA脂质体(cyclosporine A-liposome,CsA-Lip)、环孢素-A-EudragitL100纳米粒(cyclosporine A-Eudragit L100-nanoparticles,CsA-L100-NP)和环孢素A-Eudragit S100纳米粒(cyclosporine A-Eudragit S100-nanoparticles,CsA-S100-NP)以及吸收促进剂,如去氧胆酸钠(SDCh)、十二烷基磺酸钠(SDS)、泊洛沙姆(poloxamer)和羟丙基-环糊精(HP-β-CD)等在大鼠肠道各段透膜的促吸收机制及其影响因素。结果:CyA-Lip和Neoral在十二指肠、空肠的通透系数显著大于CsA-L100-NP和CsA-S100-NP(P<0.05);回肠中CsA-Lip的通透系数明显大于Neoral、CsA-L100-NP和CsA-S100-NP(P<0.05),而3种制剂之间的吸收速率差异无统计学意义(P>0.05)。结论:CsA-Lip具有更明显的促进吸收作用。 Objective:To study the mechanism to promote intestinal absorption of cyclosporine A(cyclosporine A,CsA) and the formulation factor that affects absorption.Methods:Comparing the mechanism to promote absorption across the membranes at different intestine segments of the rat and influencing factors of neural,cyclosporine A liposome(CsA-Lip),cyclosporine A-EudragitL100(CsA-L100-NP),cyclosporine A-EudragitS100(CsA-S100-NP) nanoparticles and the absorption enhancers:including sodium deoxycholate,sodium dodecyl sulfate poloxamer and H-CD.Results:Permeability coefficients of CsA-Lip and Neoralare much higher than those of CsA-L100-NP and CsA-S100-NP in the duodenum,jejunum(P 0.05);the absorption of NeoralCsA-L100-NP and CsA-S100-NP have no significant differences in the ileum(P0.05),and CsA-Lip's permeability coefficient is significantly larger than that of the other three agents(P0.05).Conclusion:The liposome has more obvious impact on promoting absorption.
出处 《抗感染药学》 2010年第4期246-250,共5页 Anti-infection Pharmacy
基金 国家科技支撑计划课题基金(编号:2006BAI09B00) 国家科技部科技型中小企业技术创新基金(立项代码:07C26223201333) 江苏省卫生厅招标课题(编号:H200630)
关键词 环孢素A 吸收 剂型 影响因素 CsA absorption formulation influencing factors
  • 相关文献

参考文献8

二级参考文献42

  • 1戴俊东 ,王学清 ,张涛 ,孟萌 ,张烜 ,吕万良 ,张强 .环孢素A pH敏感性纳米粒的制备与大鼠口服药代动力学[J].药学学报,2004,39(12):1023-1027. 被引量:12
  • 2靳浩,吴诚,梅兴国.多指标综合评价法优选阿霉素微球的制备工艺及体内的初步考察[J].中国药学杂志,2006,41(22):1723-1725. 被引量:11
  • 3KAHAN BD. Cyclosporine in drug therapy[ J]. N Eng J Med, 1989,321(25) :1725 - 1738.
  • 4LUKE DR,KASISKE BL,MATZKE GR,et al. Effect of cyclosporine on the isolated perfused rat kidney [ J ]. Transplantation, 1987,43(6) :795 -799.
  • 5LAVELLE EC,SHARIF S,THOMAS NW,et al. The importance of gastrointestinal uptake of particles in the design of oral delivery systems[J]. Adv Drug Deliv Rev,1995,18(1) :5-22.
  • 6TJAI JF, WEBBER IR, BACK DJ,et al. Cyclosporin metabolism by the gastrointestinal mucosa[ J ]. Br J Clin Pharmacol, 1991,31 (3) :344 - 346.
  • 7DREWE J,BEGLINGER C, KISSEL T, et al. The absorption site of cyclosporine in the human gastrointestinal tract[ J ]. Br J Clin Pharm,1992,33(1 ) :39 -43.
  • 8YEE G C, MC GURE T R. Pharmacokinetic drug interactions with cyclosporine ( part I ) [ J ]. Clin Pharmacokinet, 1990,19 (4) : 319 - 332.
  • 9LUKE D R, KASISKE B L, MATZKE G R,et al. Effect of cyclosporin on the isolated perfused rat kidney [ J ]. Transplantation, 1987,43 (6) : 795-799.
  • 10DESAI M P, LABHASETWAR V, AMIDON G L, et al. Gastrointestinal of biodegradable microparticles [ J ]. Pharm Res, 1996,13(12) :1838-1845.

共引文献28

同被引文献8

  • 1Xie YS, Ren XL, Pan GX, et al.The assessment of absorption of periplocin in situ via intestinal perfusion of rats by HPLC[J]. Biomed Chromatogr,2008, 22(2): 196-201.
  • 2Raoof AA, Butler J, Devane JG. Assessment of regional differences in intetinal fluid movement in the rat using a modified in situ single pass perfusion model[J].Pharm Res, 1998,15(8):1314-1316.
  • 3Sutton SC, Rinaldi MT, Vukovinsky KE, et al.Comparison of the gravimetric, phenol red, and 14C-PEG-3350 methods to determine water absorption in the rat single-pass intestinal perfusion model[J].4APS Pharm Sci, 2001,3(3):E25.
  • 4栾立标 赵暖.水飞蓟宾在大鼠小肠中的吸收特性.药学学报,2004,39:849-853.
  • 5Fagerholm U, Johansson M, Lennemas H.Comparison between permeability coefficients in rat and human[J]. Pharm Res, 1996,13:336-1342.
  • 6Lobenberg R, Amidon GL.Modern bioavailability, bioequivalence and biopharmaceutics classification system: new scientific approaches to international regulatorystandards[J]. Eurj Pharm Biopharm , 2000,50:3-12.
  • 7M Biifihrer, JY Le Cotonnec, M Wermeille, et al.Treatment of liver disease with malotilate: a pharmacokinetic and pharmacodynamic phase II study in cirrhosis[J].Eur J Clin Pharmacol , 1986,30:407-416.
  • 8陈新民,李俊松,李文,韩蕾,刘训红,狄留庆,蔡宝昌.五味子有效成分的大鼠在体单向灌流肠吸收[J].药学学报,2010,45(5):652-658. 被引量:28

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部